A Phase I, Multi-Centre, Randomized, Double-Blind, Parallel, Placebo Controlled Study of the Tolerability and Systemic Absorption of Topical Menadione Lotion as a Pre-Emergent and Emergent Treatment of Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash.
This is a clinical research study of an experimental new medication, Menadione Topical Lotion (Menadione). The medication Menadione is experimental and has not been approved for public use. Hana Biosciences, Inc., the company that is developing Menadione, is the sponsor of this study. EGFR inhibitors are used to treat non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer and head and neck cancer. One of the side effects of EFGR inhibitors is skin rash.
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society